

**“Occurrence of Virulent Strains of Helicobacter Pylori and its
Association with Endoscopic Findings in a Tertiary Centre
Teaching Hospital in Chennai”**

**DISSERTATION SUBMITTED FOR
DM MEDICAL GASTROENTEROLOGY**

**BRANCH- IV
AUGUST 2014**



**THE TAMILNADU DR.M.G.R. MEDICAL
UNIVERSITY CHENNAI,
TAMILNADU**

CERTIFICATE

This is to certify that this dissertation entitled **“Occurrence of virulent strains of helicobacter pylori and its association with endoscopic findings in a tertiary centre teaching hospital in chennai”** submitted by **Dr.AnandVadivel** to the Faculty of Medical Gastroenterology, The TamilnaduDr.MGR Medical University, Guindy, Chennai-600032, in partial fulfillment of the requirement for the award of DM Degree, Branch IV (Medical Gastroenterology) is a bonafide work carried out by him under my direct supervision and guidance, during the academic year 2011-2014.

Prof. Dr. P. Ganesh, M.D., D.M
Professor and HOD/ Guide
Department of Medical
Gastroenterology,
(DDHD@GPH, Annanagar),
Kilpauk Medical College
Chennai

Dr. P. Ramakrishnan, M.D., D.L.O
Dean,
Kilpauk Medical College,
Chennai

DECLARATION

I **Dr. V. Anand** declare that I carried out this work on **“Occurrence of virulent strains of helicobacter pylori and its association with endoscopic findings in a tertiary centre teaching hospital in chennai”** at the Department of Medical Gastroenterology, Govt. Peripheral Hospital and Kilpauk Medical College. I also declare that this bonafide work or a part of this work was not submitted by me or any other for any award, degree, diploma to any university, board either in India or abroad.

This is submitted to the Tamilnadu Dr. M.G.R. Medical University, Chennai in partial fulfillment of the rules and regulation for the D.M. Degree examination in Medical Gastroenterology.

Govt. Kilpauk Medical College

Dr. V. Anand

Chennai.

15.03.2014

ACKNOWLEDGEMENTS

I am greatly indebted to my guide **Dr. P .Ganesh, M.D., D.M.**, Professor of Medical Gastroenterology, Department of Digestive Health and Diseases, Kilpauk Medical College, Chennai, for giving me the chance to undertake this dissertation work under his guidance. Also I express my deep sense of gratitude for his constant encouragement, directions, periodical discussions, rigorous reviews and precious suggestions that helped in the shaping of my dissertation.

I express my sincere gratitude to **Dr. S. Jeevan Kumar, M.D., D.M.**, Professor of Medical Gastroenterology, Department of Digestive Health and Diseases, Kilpauk Medical College, Chennai, for giving me permission to do this dissertation in Govt. Peripheral Hospital, Anna Nagar, Chennai-102 and also his kind encouragement and review of my work, besides providing me with all the required facilities.

I also thank **Dr. T. Rajkumar Solomon, M.D., D.M.**, Professor of Medical Gastroenterology, Department of Digestive Health and Diseases, Kilpauk Medical college, Chennai for his constant encouragement and suggestions for my study.

I am extremely grateful to **Dr.P.Ramakrishnan, M.D., D.L.O**, Dean, Kilpauk Medical College for granting me permission to do this dissertation in Kilpauk Medical College, Chennai.

I am very much thankful to **Dr.M.Saraswathi,M.D.**, Professor and HOD, Department of Pathology, Kilpauk Medical College, Chennai who has helped me a lot during my dissertation.

I am very much thankful to **Dr. Sanjay Mehendale M.D., M.P.H**, Director, National Institute of Epidemiology (Indian Council of Medical Research), Ayapakkam, Chennai for supporting the study. I am thankful to **Dr.C.P. Girish KumarMSc., Ph.D,Scientist C** for Molecular characterization of *H. pylori* and support during the study. I acknowledge the contribution of **Mr.R.L. MeenaM.Sc.**, Technical Officer for PCR analysis and **Dr.S.VenkatasubramanianMSc. PhD.**, Technical Officer for Statistical analysis of my data.

I am also extremely thankful to **Dr.R.Balamurali, M.D., D.M.,Dr.G.Ramkumar, M.D., D.M.**, and **Dr.K.Muthukumaran, M.D., D.M.**, who guided me a lot.

I am also very thankful to all my **Fellow Residents** who have helped me in this dissertation.

I thank all the patients who voluntarily participated in this study, without whom this study would not have seen the light of the day.

I also thank all the paramedical staff attached to Govt. Peripheral Hospital, Anna Nagar, Chennai who have helped me in doing this dissertation work.

The Tamil Nadu Dr. M.G.R. Medical University | Medical - DUE 31-Mar-2014 | What's New

Originality | GradeMark | PeerMark | Occurrence of Virulent Strains of *Helicobacter pylori* and its association with | 8% SIMILAR | OUT OF 0

11 INTRODUCTION

Helicobacter pylori is a Gram-negative organism which is microaerophilic. It is slow-growing, possessing flagella and is spiral-shaped. It can survive in an acid environment of the human gastric mucosa.⁽¹⁾ It is the most common cause of gastritis caused by bacterial infection. Its incidence rate is as high as 50% worldwide. In World Health Organization classification, it comes under type 1 carcinogen. It causes acid peptic disease, carcinoma of stomach, and mucosa-

PAGE: 1 OF 54

Match Overview

Rank	Source	Similarity
1	Submitted to Pellissippi... Student paper	1%
2	F Stellaard, "European... Publication	1%
3	www.ncbi.nlm.nih.gov Internet source	1%
4	"Poster Session", India... Publication	1%
5	www.hpa-standardmet... Internet source	<1%
6	Robinson, K. "The Infl... Publication	<1%
7	"Abstracts for The Firs... Publication	<1%
8	Banerjee, Avisek, Asis... Publication	<1%

Text-Only Report

16112651_d. M [mge] ANAND V. VADIVEL | User Info | Messages | Student | English | What's New | Help | Logout

turnitin

Class Portfolio | Peer Review | My Grades | Discussion | Calendar

NOW VIEWING: HOME > THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

Welcome to your new class homepage! From the class homepage you can see all your assignments for your class, view additional assignment information, submit your work, and access feedback for your papers. Hover on any item in the class homepage for more information.

Class Homepage

This is your class homepage. To submit to an assignment click on the "Submit" button to the right of the assignment name. If the Submit button is grayed out, no submissions can be made to the assignment. If resubmissions are allowed the submit button will read "Resubmit" after you make your first submission to the assignment. To view the paper you have submitted, click the "View" button. Once the assignment's post date has passed, you will also be able to view the feedback left on your paper by clicking the "View" button.

Assignment Inbox: The Tamil Nadu Dr. M.G.R. Medical University

	Info	Dates	Similarity	
Medical	①	Start 13-Nov-2013 12:50PM Due 31-Mar-2014 11:59PM Post 13-Nov-2013 3:00PM	8% ■	Resubmit View

CONTENTS

SL.NO.	TITLE	PAGE NO.
1.	INTRODUCTION	1
2.	REVIEW OF LITERATURE	
3.	AIM OF THE STUDY	
4.	MATERIALS AND METHODS	
5.	RESULTS AND STATISTICAL ANALYSIS	
6.	DISCUSSION	
7.	CONCLUSION	
	BIBLIOGRAPHY	
	ANNEXURES	
	PROFORMA	
	MASTER CHART	
	ETHICAL COMMITTEE APPROVAL LETTER	

INTRODUCTION

INTRODUCTION

Helicobacter pylori is a Gram-negative organism which is microaerophilic. It is slow-growing, possesses flagella and is spiral-shaped. It can survive in an acid environment of the human gastric mucosa.⁽¹⁾ It is the most common cause of gastritis caused by bacterial infection. Its incidence rate is as high as 50% worldwide. In World Health Organization classification, it comes under type 1 carcinogen. It causes acid peptic disease, carcinoma of stomach, and mucosa-associated lymphoid tissue lymphomas (MALT).⁽²⁾

Once infection is acquired in humans, it persists throughout the life, till completion of antimicrobial therapy. In developing countries, infection prevalence is high (70–90%) compared to 25–50% in developed countries. In India, *H. pylori* prevalence is very high, in that 70–90% were with duodenal ulcer, and 50–80% were asymptomatic adults.⁽³⁾

H. pylori colonization, histologically reveals chronic gastritis mostly, remaining shows peptic ulcers and gastric adenocarcinomas. Gastric cancer is one of the three major causes of cancer-related deaths worldwide, leading to considerable socioeconomic costs. Chemotherapy for gastric adenocarcinoma does not have improved survival benefit. However, it is possible to prevent gastric cancer by eradication of the infection.

Upper GI endoscope was done, the mucosal morphology of the gastric corpus was classified into 4 patterns and correlated with histology and rapid urease test^(7,8). In invasive diagnostic methods, molecular biological methods play a major role for the detecting the species. *H. pylori* DNA have been detected in gastric biopsy specimens by PCR assays. It can also be detected in stool samples, saliva and in dental plaque. PCR assays detect the urease gene, the 16S ribosomal RNA gene sequences and adhesin gene sequences of *H. pylori*^(9,10).

Resistance to antimicrobials is increasing, necessitating an altered regimen. The treatment of *H. pylori* infection combines two to three antimicrobials, and PPI to increase the eradication rate and to decrease the antibiotic resistance. The antibiotic resistance to *H. pylori* strains is increasing, which hinders the eradication of infection. The resistance for metronidazole is 10-90% and for clarithromycin is 0 to 15%⁽³⁾. The anti *H. pylori* eradication regimen should be selected based on anti-microbial sensitivity with fewer adverse effects. Thus, culture and drug sensitivity test is a very useful tool for selecting appropriate drug regime.

Thyagarajan et al. (2003) in their large multicentric study report an overall resistance of around 78% to metronidazole, 45% to clarithromycin and 33% to amoxicillin. Multiple resistance was seen in 43% isolates. The resistance to Metronidazole was higher in Chennai (88%) and Hyderabad (100%). Resistance to Ciprofloxacin and tetracycline was less than 4%⁽¹¹⁾.

Several virulence genes from *H. pylori* have been identified and their role in pathogenicity has been documented. These include the cytotoxin associated gene (Cag A), vacuolating cytotoxin associated gene (vac A), epithelial gene (ice A), blood group antigen binding adhesion gene (Bab A), and duodenal ulcer-promoting gene A (dupA). Cag A plays a role in duodenal ulcer, gastric cancer and gastro mucosal atrophy and Vac A in peptic ulceration. Mukhopadhyay et al. (2000) have reported 80 to 90% of Calcutta strains carry the cag pathogenicity island and vacAs1 alleles of the vacA are highly toxic ⁽⁴⁾.

Mishra et al. (2002) have reported that all isolates from Lucknow in their study, to possess vacA and about 96.2% of isolates from Lucknow were cagA positive ⁽⁵⁾

Udhayakumar et al. (2009) have reported 96% of their isolates from Chennai to be CagA positive and 60% were Vac m2 subtype ⁽⁶⁾.

We carried out this study in our centre to identify the mucosal patterns of *Helicobacter pylori* associated gastritis in the gastric corpus using video upper G.I endoscopy and study the frequency and relevance of association of virulence factors and clinical presentation among *H. pylori* infected individuals.

REVIEW OF LITERATURE

REVIEW OF LITERATURE

Chronology / Historical perspectives

Year :	Event
1886	Jaworski's- Describe the spiral organisms in gastric washingsof humans.
1893	G. Bizzazero. - Spiral organisms confirmed in animals.
1900	Salomon - Spiral bacteria infecting dogs can be transmitted to mice
1906	Kreinitz - Infecting stomach was confirmed .
1910	Schwartz - "No acid no ulcer"
1924	Luck and Seth - Urease in the human stomach(natural)
1940	Freedberg and Baron - Spirochetes in autopsied .
1953	Dintzis and Hastings - Relationship between urease and bacteria
1967	Susumu Ito - Campylobacter-like organisms in gastric epithelialcell.
1982	Marshall and Warren - Accidental culturing of <i>H. pylori</i> done.
1985	Marshall - Self-induced infection ^[12] .
1992	Covacci et al. - Sequence the CagA gene cause duodenal ulcers. (first virulence factor)
1994	Parsonnet et al. - Association between lymphomas GIT and <i>H. pylori</i>
2002	Maastricht Consensus Report, - "test-and-treat" strategy for <i>H.pylori</i>
2005	Warren and Marshall - Awarded the Nobel Prize in Physiology or Medicine for their work on <i>H. pylori</i> and PUD

Bacteriology

Helicobacter pylori is a gram negative helical bacteria about 3 μm long with a diameter of 0.5 μm . It is a microaerophilic, i.e. requiring very low concentrations of oxygen. It has hydrogenase activity by which it gets energy by molecular hydrogen oxidation. Other enzymes produced by these bacteria are urease, oxidase and catalase. Like other Gram-negative bacteria, its outer-membrane is made up of lipopolysaccharide and phospholipids.




FIGURE 1: *Helicobacter pylori*.

India Scenario

In a developing country like India with vast rural population, majority of people belongs to low socio-economic group, where the prevalence of *H. pylori* is 80 percent. The Clinical manifestation of *H. pylori* infection in India is peptic ulcer disease, particularly duodenal ulcer disease. When compared to gastric ulcers the ratio is 8:1 and 30:1. Singh et al. "calculated the point prevalence of active peptic ulcer disease as 3% with a lifetime prevalence of 9 per cent". The outcome from a *H. pylori* infection is predicated based on the pattern of gastritis^[13]. In antral predominant gastritis, gastric acid secretion is normal but inhibitory function of

antrum is decreased which leads to uncontrolled acid secretion and forms duodenal ulcer. In pan-gastritis, acid secretion is decreased resulting in atrophic gastritis which is more prone for gastric cancer^[14].



FIGURE 2 : Global prevalence of *H. pylori*.

Diet is an important environmental factor that plays a major role in the *H. pylori* associated gastric diseases. Tropical diet consists of plenty of fruits and vegetables which cause non-atrophic gastritis and duodenal ulcer.^[15,13] Seasonal diets, predominantly the salt preserved foods lack fresh fruits and vegetables which leads to pan-gastritis and gastric ulcers. In south India duodenal ulcer prevalence is very high due to these environmental factors play a major role.

Gastric cancer incidence rate is 2 to 57 persons per 1 lakh^[16]. The population of India according to [CENSUS 2011] is approximately 1.2 billion people. The prevalence of *H. pylori* was 60 %, that means more than 726 million people would be infected with *H. pylori*^[17]. “The estimated prevalence of duodenal ulcers

in India is 3 per cent and means that at least 18 million people could need anti-*H. pylori* therapy (approximately 50,000 per day if treated over one year)".

Direct transmission

Transmission of bacteria from person to person occur by fecal- oral, oral - oral, and gastro - oral^[18].

1) Oral-oral transmission

H. pylori was previously thought as oral microbes, ^[19] although it is not prevalent among the dentist and dental workers^[20,21]. Recent studies stated that persons exposed to diarrhoea caused by *H. pylori* is a high risk for new infection ^[22].

2) Gastro-oral transmission

Since *H. pylori* commonly inhabits the human stomach, it was suggested that gastric juice reflux is the cause for direct gastro-oral route. ^[23] Several studies reported that even the vomitus of infected subjects cause transmission. ^[24] Among infected siblings ¹³C urea breath test holds good for detection of organisms ^[25].

3) Feco-oral transmission :It is unlikely to occur via feco- oral transmission since bile has bactericidal effect. ^[18]

II. Indirect transmission

The sources and the reservoir of infection were investigated from food, animals, and water sources based on its morphology and DNA study. But no evidence suggested them as primary vehicles of transmission.

***H. pylori* reservoirs**

Hypothesis	Evidence
Food	
Unhygienic food	Positive correlation
Raw vegetables	likelihood of infection
Sheep and cow milk	
Animals	
Most animal species act as <i>H. pylori</i> reservoirs	Sheep/cat /rhesus monkeys /houseflies /cockroaches
Animal-to-human	Dore et al. stated that <i>H. pylori</i> is a zoonotic, occupational infection animals.
Water	likelihood of infection

Genetic and Environmental Determinants

Age

The prevalence increases with age in developing and developed countries . The prevalence of infection was high in adults .

Genetic and Ethnic factors

Many studies reported marked differences in *H. pylori* seroprevalence among various ethnic and racial groups ^[26]. It was suggested that genetic factors also influence *H. pylori* infection, based on study in monozygotic and dizygotic twins. ^[27].

Gender

H. pylori infection is highly prevalent among men . ^[28]

Interfamilial relations

Several studies reported as spread of infection among families in children is from adults. ^[29] The interfamilial spreading is mainly caused by mother-to-child transmission and spouse-to-spouse transmission ^[30].

Socioeconomic factors

H. pylori infection is highly prevalent among lower socioeconomic groups. The socioeconomic status includes social class, income and also includes standard of living, sanitation, urbanization, and educational level ^[11].

Crowding index (Density of living)

H. pylori infection is highly prevalent among densely crowded areas. The risk factors include sharing a bed, crowding of houses and increasing household contact.^[32],

Factors and pathogenesis

Microbial virulent factors

Bacterial virulence factors are associated with inflammation of gastric mucosa^[33]

CYTOTOXIN

Leunk et al. first described the vacuolating cytotoxin (VacA) in eukaryotic cells.^[32] The cytotoxin produced by the organism is responsible for peptic ulcer disease. The VacA protein has abiological activity which increases at acidipH. VacA is activated by acid pH and is highly associated with mucosal damage.

Atherton et al stated that “there are two divergent regions in vacA. One is in the second half of the signal sequence (s1a/s1b and s2) and the other is in the mid-part of the gene (m1 and m2)”.

The s1/m1 strains are highly virulent allelic than s1/m2 strains, gastric epithelial damage high among m1 strains^[34] and mucosal infiltrates with lymphocyte and neutrophils is usually seen among s1 strains^[34].

Cytotoxin associated gene A

cagA is commonly encountered gene of *H. pylori*. It has a molecular weight of (120–140 kDa) and is immune-dominant, seen in 60% strains^[35].

CagA strains result in increased immune responses at mucosal level and severe gastric inflammation. Thus CagA positive strains have a strong association with atrophic gastritis, acid-peptic disease and gastric cancer.

A 40 kilobase pathogenicity island (cag PAI) includes cagA and other 30 genes.

The gene products from cag PAI assess the response of epithelial chemokine using isogenic mutant strains.^[36] CagA serves as a marker for virulent organism.

Different genes in the cag PAI have a varied response in epithelial chemokine. Cag PAI genes code for protein which has a secretory function in host epithelium^[37].




FIGURE 3- Equilibrium of interactions between *H. pylori* and its host.

Lipopolysaccharide

The *H pylori* lipopolysaccharide [LPS] has low immunological activity and low biological activity due to its lipid A component which is in a phosphorylated state and is responsible for chronic inflammation and autoimmune responses in the stomach at mucosal level. Similarity exists between LPS O-specific antigen and host antigen –Lewis X, Lewis Y blood group antigens^[38]. This molecular mimicry plays a role in H⁺, K⁺ proton pump mechanism where the anti- Lewis Y antibodies produced by *H pylori* binds to Lewis Y epitope leading to atrophic gastritis. Lewis antigens more frequently expressed on cagA positive strains^[39].

Immune mediated damage:

The inflammatory response by host immune system also induces damage of gastric mucosa. Histologically, it is characterised by infiltration of lymphocytes, plasma cells, monocytes, and neutrophils, into gastric mucosa^[40].

Neutrophil activation

Activated neutrophils is the first inflammatory response to *H pylori*. HP-NAP (Neutrophil activated protein) and LPS (lipopolysaccharides) via superoxide stimulate neutrophils. Epithelium secretes chemokines like IL-8 and regulated

cytokines such as TNF- α and IL-1. Increased expression of ICAM-1 and VCAM-1 cause neutrophil endothelial adhesion and extravasation.


T cell activation:


Chronic gastritis frequently secrete interferon (IFN) γ by *H. pylori* specific CD4⁺ T cell clones. *H. pylori* infection also stimulate IL-12 production from peripheral blood leucocytes and induce Th1 response. Peptic ulcer disease is induced by Th1 response.

Complement activation

Infection activates the classic pathway of complement and leads to neutrophil chemotaxis and epithelial damage. Berstad and colleagues states that activation of both complement pathways.

Features of Gastritis The Acute Phase : Initially subclinical.





This acute infection spontaneously resolves in a minor population, particularly in children. In most of the patients, infection fails to resolve and gradually develops into chronic active gastritis in 4 weeks.

Active Chronic Gastritis

Acute inflammatory response augmented by lymphocytes and plasma cells in the mucosa leads to production of antibodies and cytokines as a second-line response involves production of lymphocytes and plasma cells. Gastric mucosa containing lymphoid tissue develops into gastric marginal zone (B-cell) lymphoma called MALToma.

Atrophy

Gastric Atrophy is defined as “loss of glandular tissue from repeated mucosal injury due to long-standing infection”. It leads to erosion or ulceration of the mucosa, prolonged inflammatory process causing fibrous replacement. Mucous metaplasia is defined as parietal cells are replaced by mucous cells.

H. pylori prevalence is inversely related to glandular atrophy due to

1. Colonizes only in gastric epithelium;

2. Survives only in acidic environment .⁽⁴²⁾.

Intestinal Metaplasia(IM)

It is replaced by gastric epithelium into intestinal epithelium and is always associated with abnormal growth stimulation ⁽⁴³⁾. IM is most commonly associated with elderly, commonly seen in the antrum, associated with gastric ulcer and bile reflux.⁽⁴⁴⁾.

Antral Predominant Gastritis

H. pylori in the presence of urea and acidic environment



To maintain proton motive force (PMF) in periplasmic membrane.



Cytoplasmic urease acts on urea entering the bacterium to produce ammonia.



Ammonia preserve the PMF by maintaining a pH of 6.2 in the periplasmic space⁽⁴⁵⁾.




FIGURE 5 -Model of the mechanism of action of UreI and HP0244

Corpus Gastritis

A corpus gastritis is seen in small group of patients. Corpus-predominant gastritis has low acid output due to release of IL-1 from parietal cell which is acid-inhibitory cytokines .

Pathogenesis of Duodenal Ulceration :

Gastric Metaplasia

Hyper-gastrinemia and increased sensitivity to gastrin present in duodenal ulcer causes unneutralized acid in the duodenal bulbresulting in compensatory gastric metaplasia[mucus-secreting cells]⁽⁴⁶⁾.

Active Chronic Duodenitis

H. pylori gets attached to gastric epithelium, it is the site where polymorphs migrate into epithelium. In duodenum, gastric metaplasia is associated with polymorph response. Identification of *H. pylori* organism is difficult in duodenal biopsies. The prevalence rate of duodenal ulcer and gastric metaplasia is diagnosed by histology, culture, and rapid urease tests.

Ulceration

Wyatt et al. emphasized the relationship between active chronic duodenitis, *H. pylori* gastritis, acid-induced gastritis, and metaplasia.⁽⁴⁷⁾

H. pylori spread from the stomach to duodenum → In duodenum acid-induced metaplasia → Chronic inflammation → duodenal ulceration.

Gastric Ulceration

Gastric ulceration occurs due to an intense inflammatory response secondary to *H. pylori* infection at the antral corpus transitional zone. This intense inflammatory response due to *H. pylori* at the acid-gradient transitional zone is based on the local environment and optimal pH, or induction of stress proteins resulting in release of inflammatory products.

Gastric cancer

Gastric adenocarcinoma caused by *H. pylori* infection is associated with other factors like host factors, genetic factors, strain of bacteria, duration and environmental factors.

In Correa pathway cancer, Due to DNA alterations occurred by *H. pylori* infection and inflammation. It leads to recruitment and bone marrow-derived cells engraftment. Altered epithelial cell proliferation and apoptosis which leads to atrophy. *H. pylori* with nitrate reductase activity, leads to adenocarcinoma. Corpus-predominant atrophy, or the loss of specialized glandular cell are the first step in cancer.




FIGURE 6-Model representing the role of *H. pylori* and other factors in gastric carcinogenesis, based on the cascade proposed by Correa et al.

Role of Bacterial strains

FlaA and FlaB proteins - 1) Motility toward epithelial cells of the stomach

2) ECM and mucus altered and cause decrease Viscosity.

UreA/UreB complex - Buffering of stomach and survives.

Hop proteins	- Adhesion of bacteria to epithelium .
BabA gene	- Adhere to fucosylated Lewis B blood group antigen .
babA2 gene	- Binds to epithelial cells and associated with adenocarcinoma.
TFSS	- Secreting system (injects cag)
cag pathogenicity island	- Severe inflammation atrophic gastritis and adenocarcinoma.
vacA gene	- T cell activation inhibitor.
cage	-Altered apoptosis and inflammatory response in host.

Non-steroidal AntiInflammatory Drugs (NSAIDs) with *H. pylori*

A study conducted on *H. pylori* association with NSAIDS based on mucosal erosions, haemorrhage and ulcers following 1 week of NSAIDS intake.⁽⁴⁸⁾ It revealed no association between *H pylori* and normal population.

Extraintestinal manifestations:

Ischaemic heart disease & cerebrovascular disease

H. pylori may influence IHD by cross mimicry between vascular endothelium, such as heat shock proteins[HSP], leading to pro-coagulable state due to infection^[49].

Functional Vascular Disorders

H. pylori infection is associated with idiopathic migraine and Raynaud's phenomenon^[50]

Immunological diseases

Several studies reported, After eradication of *H. pylori* patients with autoimmune diseases (HSP, Sjögren's syndrome, and idiopathic thrombocytopenia)^[51]. Some cases of extragastric MALT type of lymphoma improved after treatment for *H. pylori* infection.^[52]

Skin diseases

H. pylori cytotoxic strains cause mast cell degranulation which triggers development of urticaria^[53] *H. pylori* infection strongly associated with Acne rosacea and alopecia areata^[54].

Liver and biliary tract

Elevated blood concentrations of ammonia decrease on treating *H. pylori*.^[55] A recent study established a relation between *H. pylori* in bile samples with

CagA protein and aminopeptidase N, which induces cholesterol aggregation. But association with *H. pylori* and cholelithiasis is not known.^[56]

Others complications

H. pylori infection associated with sideropenic anaemia^[57], sudden infant death and decrease growth rate in children^[58].

INVESTIGATIONS:

Invasive techniques like tissue biopsy was followed earlier. With advancement in diagnostic field, non invasive tests like molecular biology has become popular, but not ideal for routine use^[59]

Gastric endoscopic pictures of *H. pylori* infection (Taiwan classification)

Morphology of the gastric mucosa was classified into 4 types, observed with upper GI endoscopy.

Type 1 - “Cleft-like appearance extending along the longitudinal axis of gastric body”.

Type 2 - “Red dots arranged uniformly”

Type 3 - “The mosaic pattern without a focal area of hyperemia.”

Type 4 - “The mosaic pattern with a focal area of hyperemia .”^[60]




FIGURE 7- Mucosal patterns in endoscopy.

In gastric ulcer or gastric atrophy , biopsy sampling was taken from the nearby non-atrophic mucosa. Gastric biopsy is the specimen for culture and sensitivity.^[61]

Invasive techniques:^[62]

- Histopathological examination
- Culture and sensitivity
- Rapid urease test(RUT)
- Polymerase chain reaction (PCR)

Culture

H.pylori are slow growing and fastidious organism. It needs special media and growth environment hence it is difficult to culture. Culture enables performance

of antimicrobial susceptibility testing. It helps to know about treatment efficacy, and re-infection identification. Though the sensitivity rate is 92% , In refractory disease, for prediction of treatment outcome it has limited role.

Histology

Though *H pylori* infestation can be detected with routine hematoxylin and eosin staining, it is not sensitive, hence requires special stains such as Giemsa, silver, or immune stains which are specific. Histologic examination is the gold standard with reported sensitivity and specificity 95% and 98%, respectively. Histology and culture does not provide rapid diagnosis.^[63]

Biopsy urease test

Rapid urease test is highly sensitive and cost effective. It is combined with culture or histology. Commercial kits are highly accurate but expensive.

Also called CLO test (Campylobacter-like organism test), performed to detect urease producing organism. The bacterial enzyme urease converts urea to ammonia and CO₂, resulting in colour change of the broth due to increase in pH. (phenol red acts as a pH indicator.)

Urea is produced during decarboxylation of the amino acid arginine in the urea cycle. It is water soluble hence it released from human body when present in excess.

H. pylori is more efficient in hydrolyzing urea than other enteric bacteria, hence it is named as "rapid urease-positive" organism.

Polymerase Chain Reaction (PCR)

PCR – To detect *H. pylori* in various samples.

Indications :

1. Research
2. Difficulty in culturing.
3. For epidemiologic studies by testing stool or drinking water
4. Tissue - “real time” antibiotic resistance.

Non-invasive techniques

These methods are comparatively inexpensive and avoid hazards of endoscopy,

- Serology (ELISA)
- Urea breath tests (UBTs)
- Stool antigen tests

Serology

Serology is primarily done by ELISA IgG and IgA. ^[64] IgG is the primary detection modality. The sensitivity is 90% -100% and specificity is 76% - 96 %.

Serology has a high negative predictive value and a poor positive predictive value in a low prevalence area. Serology has a limited value in detection of eradication of *H. pylori* due to the persistence of immunoglobulins.

Urea breath tests (UBTs)

It is currently the most commonly used non – invasive technique to identify *H. pylori* infection.^[65] Urea is labelled with either ^{14}C or ^{13}C . The specificity and sensitivity is about 95%, thus making false-positive results a rarity. Sensitivity of the test can be improved by avoiding antibiotics for 4 weeks and anti-secretory drugs for 1 week before breath test. UBTs can be used for assessment of eradication therapy. UBT is not accurate in post gastrectomy status.

Stool Antigen Tests

The *H. pylori* stool antigen (HpSA) test is one of the newer diagnostic modalities to diagnose *H. pylori*.^[66] It is a non-invasive enzyme immunoassay with a sensitivity and specificity of around 95% with the advantage to confirm eradication.

Current recommendations for testing

1. For an initial diagnosis of *H. pylori* a UBT or stool antigen assay is opted because of their non-invasive nature and their ability to detect active infection.

2. Serology excludes *H. pylori* infection, and for active infections positive serology results requires a confirmatory test.
3. Biopsy should be done in patients undergoing a diagnostic endoscopy for a suspected ulcer or MALT lymphoma. If histopathology is not required Biopsy urease testing can be done, in patients not on anti-secretory or antibiotics.
4. An UBT or stool antigen test can be done after 4 to 6 weeks of therapy if clinically indicated for confirmation of successful eradication of infection.
5. In a complicated ulcer disease or other mucosal abnormality, after 4-6 weeks of treatment endoscopy should be done for follow up.

Treatment

Indications for anti-*H. Pylori* regimen

The Canadian *H. pylori* Consensus Conference recommend that it is ideal to treat all *H. pylori*-positive patients. Even if another aetiology is suspected along with which documentation of eradication of the infection would be appropriate.^[67]

Recommended primary therapies include: clarithromycin or metronidazole, amoxicillin, Proton pump inhibitor (clarithromycin-based triple therapy) for 14 days or 10 to 14 days of treatment with metronidazole, bismuth, tetracycline, PPI or H2RA, (bismuth quadruple therapy). Intention-to-treat (ITT) analytical studies have shown an eradication rates hover around 70–80%^[68]. Trials have documented that amoxicillin or metronidazole have equal efficacy in a

clarithromycin-based triple therapy so metronidazole can be substituted in place of amoxicillin in patients allergic to penicillin. Bismuth quadruple therapy is an alternative for penicillin allergy patients who had been previously treated with a macrolide based regimen .

An alternative to triple and quadruple therapy is the sequential therapy which is amoxicillin and Proton Pump Inhibitor for five days followed by , PPI tinidazole and clarithromycin for fivedays. Sequential therapy has been found to be superior in clarithromycin resistant areas.

Culture and sensitivity are rarely performed due to the expense lack of availability, the usefulness of such testing in providing alternative regimens in patients who have failed the primary treatment modality.

Bismuth based quadruple therapy is “salvage” therapy .This salvage regimen is widely available, inexpensive, and relatively effective.

Newer regimens

Triple therapy -based on Levofloxacin(levofloxacin, and amoxicillin PPI).Rifabutin, is an alternative to clarithromycin (eradication rate- 38% to 91%).).

AIM:

AIM:

1. To identify the mucosal patterns of *H. pylori* associated gastritis using video upper G.I endoscopy.
2. To study the frequency of *H. pylori* virulence factors and their correlation with the clinical presentation.
3. To determine the association of virulence genes of *H. pylori* to that of the mucosal changes on endoscopy and histopathology.

MATERIALS AND METHODS

MATERIALS AND METHODS

This is a hospital based cross-sectional study conducted in the Department of Digestive Health and Diseases (DDHD), Government peripheral hospital, Chennai from December 2012 to January 2014. 150 patients with symptoms of dyspepsia were included in the study. The study was initiated after obtaining approval by the ethics committee of Kilpauk medical college. Patients were enrolled following the inclusion / exclusion criteria provided below. Written informed consent was obtained from all participating subjects in regional language (Tamil). Privacy and confidentiality was ensured.

Inclusion criteria

1. Uninvestigated dyspepsia
2. Active gastric ulcer or duodenal ulcer
3. Gastric MALT-lymphoma (low grade)

Exclusion criteria

1. Structural cause for dyspepsia (hiatus hernia, GERD)
2. Metabolic cause for dyspepsia (uremia, ischemic heart disease, biliary colic, pancreatitis)
3. Recent use of proton pump inhibitor, antibiotics, bismuth-containing compounds
4. Patients who refused consent.

All patients were investigated for CBC, Blood glucose, blood urea, serum creatinine, ECG, Ultrasound abdomen, blood grouping & typing and Gastroscopy

Six biopsy samples were taken directly from the suspicious sites (antrum or corpus).

Two samples were sent for histological analysis at Department of Pathology, Kilpauk Medical College

Histopathological examination - Specimens were placed in 10% formalin solution and routinely processed.

Two samples for a rapid urease test.

Two samples for culture and antibiotic susceptibility testing, Genomic DNA extraction.

Each antral and corpus specimens for culture were transported to the NIE laboratory in a suitable transport medium i.e. sterile isotonic saline if transported within 6 h or in sterile BHIB at 40C in a vaccine carrier / thermocol box with frozen gel packs.

Composition of Urea Broth:(Rustigian and Stuart, 1941*) – Ref: Baltimore Biological Laboratories, Maryland, USA

Ref: Myer's and Koshi's- CMC Vellore “Manual of Diagnostic Procedures in Medical Microbiology and Immunology/ Serology”

Urea	-	2.0gm
Monopotassium Phosphate (KH ₂ PO ₄)	-	0.91 gm
Disodium Phosphate (Na ₂ HPO ₄)	-	0.05 gm
Yeast Extract	-	0.01 gm
Phenol Red	-	0.001 gm
Distilled water	-	100ml

The ingredients was dissolved in distilled H₂O and pH as adjusted to 6.8. The base mediums was sterilized by autoclaving at 115⁰C for 10minutes and then add filter sterilized urea solution to the autoclaved base.The pH was adjusted to 6.8. 1ml of broth was distributed in small sterilized vials.




FIGURE 8- Rapid Urease Broth negative (L) and Positive (R)reactions for *H. pylori*.

Transport medium

Endoscopy specimens were transported to the NIE laboratory in a suitable transport medium i.e. sterile isotonic saline if transported within 6 h or in sterile BHIB at 40C in a vaccine carrier / thermcol box with frozen gel packs .

Brain Heart Infusion Broth :

Beef Heart Infusion Form	- 250 gm/ liter
Calf Brain Infusion Form	- 200 gm/ liter
Dextrose	- 2 gm / liter
Proteose peptone	- 10 gm / liter
NaCl- 5 gm / liter	
Disodium Phosphate	- 2.50 gm / liter

37gms of above mentioned compounds were dissolved completely in 1000ml of distilled water, pre-autoclaved at 121⁰C for 15 minutes adjust pH to 7.4. 1ml of broth was distributed in small sterilized vials.




FIGURE 9- Transport Medium - Brain Heart Infusion Broth.

Histopathology

One portion of the biopsy material was sent for staining with hematoxylin and eosin for histopathological examination at Kilpauk Medical College. Scoring for gastritis and gastritis activity, from mild to severe, was done based on the level of infiltrating lymphocytes and neutrophils, respectively. Grading in bacterial density was performed by observing the bacterial count present on gastric epithelia. The presence of large bacterial clumps was considered as severe, whereas a single or small group of two to three organisms was graded from mild to moderate. Other important parameters including atrophy, intestinal metaplasia, and chronic or active gastritis if any, was documented.




FIGURE 9- *H. pylori* in antrumFIGURE 10- Intestinal Metaplasia

Culture

Culture of tissue homogenate was attempted on 5-7% sheep blood agar containing Skirrow's supplement (Oxoid). The plates were incubated at 37°C under microaerophilic conditions (10% CO₂) for upto 10 days. It was planned to perform antibiotic susceptibility testing for any positive culture .

Genomic DNA extraction from biopsy specimen

DNA from each biopsy specimen was extracted using the genomic DNA purification kit (Himedia), according to the manufacturer's instructions.

Extracted DNA was stored at -20°C until PCR analysis. PCR assays for glmM gene and virulence genes (*vacA*, *cagA*) was carried out as per standard protocols. Analysis for the human β -globulin housekeeping gene will be carried out by PCR to assess the quality of extracted DNA.




Figure -11

Fig: (A). Amplification of *cagA* gene(394 bp), M=100bp ladder, Lane 1 Negative control and Lane 2 to 4 biopsy samples
(B). Amplification of *vacA* gene (Allele m1 (401 bp) and Allele m2 (476bp), M=100bp ladder, Lane 1 Negative control, Lane 2 to 3 Allele m2, Lane 4 to 5 Allele m1 and Lane 6 Allele m1 m2

All endoscopies were performed by experienced endoscopist.

Ethical committee approval was obtained from Kilpauk medical college before starting the study.

Written informed consent was obtained from all participating subjects in regional language (Tamil). Privacy was ensured.

Statistical analysis was done by statistical analysis software SPSS(version 19.0)

RESULTS

RESULTS

A total of 147 patients were included for the study based on inclusion criteria.

Age distribution

Among 147 patients, 50% of cases were from the age group 21-39 years followed by middle age(29%). Out of them *H. pylori* positivity (PCR) was seen in 35 patients and 12 patients respectively . Table 1

Age (years)	Frequency (%)
<20	9 (6)
21-39	74 (50)
40-59	40 (29)
>60	22 (15)
Total	147

Table1. Age wise distribution of study participants

Gender distribution

Among the 147 patients in our study, 105(71%) were males and 42 (29%) were females (Table:2). Out of them *H. pylori* positivity (PCR) was seen in 42 patients and 17 patients respectively. Table 2

Sex	Frequency (%)
Male	105 (71)
Female	42 (29)
Total	147

Table2. Gender wise distribution of study participants

Presenting complaints : In our study, abdominal bloat(27%) was the most common symptom, followed by epigastric pain(24%) & postprandial fullness (14%). The less common symptoms were early satiety (5%), atypical chest pain (4%), & nausea & vomiting(1%). In 15% of patients symptoms were relieved by antacids.

36 patients had epigastric pain out of which 16 patients (44.4%) showed positivity for *H. pylori* and 39 patients had Abdominal bloating out of which 15 patients (38.4%) showed positivity for *H. pylori*. *H. pylori* positivity among different clinical symptoms was not statistically significant (P =0.0714).


Personal habits : In our study, frequency of alcohol(26%) & smoking(22%) was almost equal. But majority(29%) of them had no risk factors. Among the patients with the above listed personal habits ,occurrence of PCR positivity is more or less equal varying from 36% to 50% .Though PCR positivity was slightly more in risk group(alcohol,smoking) the finding was not statistically significant (P:0.968).

Past history : Past history was not significant in majority of the patients 40%. 28% had diabetes mellitus, followed by Hypertension in 17% and Drug intake like ASA ,NSAID in 15%. Among patients with drug intake, 11/22 patients showed PCR positivity. In 41 Diabetic patients 20 had PCR positivity. Though PCR was positive in almost 50% of patients with drug intake and diabetes group, overall it was not statistically significant (P value:0.217)

Endoscopy findings

Among 147 patients, abnormal findings was seen in 69 % and 31% had normal mucosal study. Out of 69% , type 1 & 2 gastritis was seen in 22%, type 3&4 was observed in 31%, duodenal ulcer in 12% and Gastric ulcer in 5% of participants. Figure 12.

Figure 12: Distribution of endoscopic findings



Histopathological features : Our study showed 84 %patients had gastritis and 16 % patients had precancerous lesions i.e., atrophic gastritis and intestinal metaplasia and *H. pylori* was seen microscopically in only 2% of participants. Table 3

Table 3: Distribution of histopathological findings

Histopathological Examination (HPE)	Frequency (%)
Chronic non -specific gastritis	83 (56)
Erosive gastritis	24 (16)
Nodular gastritis	14 (10)
Intestinal metaplasia	17 (12)
Atrophic gastritis	6 (4)
H. Pylori	3 (2)
Total	147

Percentage of RUT and PCR positivity

Among 147 patients, RUT was positive in 46 % and PCR positive in 40% of the patients. Table 4.

Table 4: Results of RUT and PCR analysis

Rapid Urease Test (RUT)	Frequency (%)	PCR	Frequency (%)
Positive	68 (46)	Positive	59 (40)
Negative	79 (54)	Negative	88 (60)
Total	147	Total	147

Comparison of RUT with PCR positivity

On comparing RUT with PCR, RUT showed sensitivity of 71.19 % and specificity of 70.45 % , PPV of 61.76% and NPV of 78.48%. Table 5.

Table 5: Comparison of RUT & PCR findings

RUT	PCR		Total
	Positive	Negative	
Positive	42	26	68
Negative	17	62	79
Total	59	88	147

Comparison of endoscopic findings with PCR

In PCR positive group, sensitivity of abnormal endoscopic findings are 69.49% and specificity of 31.82%. PPV & NPV of 40.59% & 60.87% respectively. Table 6

Table 6: Comparison of endoscopy findings with PCR

OGD	PCR		Total
	Positive	Negative	
Positive	41	60	101
Negative	18	28	46
Total	59	88	147

Comparison of endoscopy positive findings with PCR

Among abnormal findings, PCR positivity was high in Type 3 & 4 gastritis in comparison to Type 1 & 2, with sensitivity of 84.38% and specificity of 60%. Even in normal mucosa PCR was positive in 39% of patients as we are using conventional endoscopy rather than magnification endoscopy. Overall association of endoscopic positivity and PCR is statistically significant ($P = 0.003$). Table 7

Table 7: Endoscopic positivity & PCR results.

OGD	PCR		Total
	Positive	Negative	
Type 1 + Type 2	5	27	32
Type 3 + Type 4	27	18	45
Duodenal ulcer	7	10	17
Gastric ulcer	2	5	7
Normal mucosa	18	28	46
Total	59	88	147

Comparison of endoscopy positive findings with Cag positivity

In endoscopy Cag positive patients were 37, out of which 21 (56.75%) had gastritis including all types. Cag positivity was more in type 3 & 4 gastritis and duodenal ulcer groups. But among gastric ulcer, none was positive. p value was 0.059. Table 8

Table 8 : Comparison of endoscopy positive findings with Cag positivity

OGD FINDINGS	Cag gene		Total
	Positive	Negative	
Type 1 + Type 2	4	28	32
Type 3 + Type 4	17	28	45
Duodenal ulcer	5	12	17
Gastric ulcer	0	7	7
Normal mucosa	11	35	46
Total	37	110	147

Comparison of endoscopy positive findings with Vac positivity

Out of the 53 VacA positive patients, 24(53%) had type 3 & 4 gastritis and 5(15%) had type 1 & 2 gastritis. VacA positivity was more common in type 3 & 4 gastritis ($s_1m_2 > s_1m_1$) and duodenal ulcer in comparison with Cag gene. Both s_1m_1 and s_1m_2 were positive in 11%. Table 9.

Table 9 : Comparison of endoscopy positive findings with Vac positivity

OGD findings	Vac genes				Total
	M1+	M2+	M1+M2	Negative	
Type 1 + Type 2	1	3	1	27	32
Type 3 + Type 4	8	14	2	21	45
Duodenal ulcer	2	2	1	12	17
Gastric ulcer	0	1	0	6	7
Normal mucosa	9	7	2	28	46
Total	20	27	6	94	147

Comparison of Histopathological features with Cag gene

Among 37 Cag positive patients, 27 patients presented with gastritis and 10 patients had precancerous lesions i.e., atrophic gastritis (2/10) and intestinal metaplasia (8/10). Out of 27 patients who had gastritis, 17 (62%) had Chronic non-specific gastritis, 5 (18.8%) had Erosive gastritis, 4 (14.8%) had Nodular gastritis and 1 (3.7%) had *H. pylori* gastritis. Around 72.9% Cag positive patients were associated with gastritis.

Cag only positive subgroup gastritis was seen in 4 (14.8%) of the 27 patients. In the Cag subgroup only one person had a precancerous lesion.

Out of 37 Cag positive patients, 22 patients had both Cag and Vac gene positivity. Table 10

Table 10: Comparison of histopathological features with Cag gene

HPE	Cag A		Total
	Positive	Negative	
Chronic non -specific gastritis	17	66	83
Erosive gastritis	5	19	24
Nodular gastritis	4	10	14
Intestinal metaplasia	8	9	17
Atrophic gastritis	2	4	6
<i>H. pylori</i>	1	2	3
Total	37	110	147

Comparison of Histopathological features with Vac gene

Among 53 Vac positive patients, 20(37.7%) patients had s₁m₁, 27(50.9%) patients had s₁m₂ and both positive were seen in 6(11.4%) patients.

In the VacA only positive sub group, gastritis was seen in 17 (44.7%) patients out of the 38. On subtyping, 6(32.2%) patients had s₁m₁, 9 (52.9%) patients had s₁m₂ and 2(11.7%) persons had both s₁m₁ and s₁m₂.

In the VacA positive group, precancerous lesions i.e., atrophic gastritis and intestinal metaplasia were seen in 7 patients. On subtyping 6(85.7%) patients had s₁m₂ and only 1(14.2%) had both s₁m₁ and s₁m₂.

11/17(64.7%) patients with intestinal metaplasia showed VacA positivity, in which 8/11 patients (72 %) were positive for s₁m₂. Table 11.


Table 11: Comparison of Histopathological features with Vac gene

HPE findings	Vac gene				Total
	M1+	M2+	M1+M2	Negative	
Chronic non -specific gastritis	8	9	4	62	83
Erosive gastritis	5	5	0	14	24
Nodular gastritis	3	2	0	9	14
Intestinal metaplasia	3	7	1	6	17
Atrophic gastritis	1	3	0	2	6
H. pylori	0	1	1	1	3
Total	20	27	6	94	147

Distribution of disease positivity

Overall, 69 % patients had abnormal endoscopic findings, 46 % had RUT positive and 40 % had PCR positive. Rapid urease test had a sensitivity of 71%, specificity of 70.45 % and cost effective which can be carried out in the endoscopy suite. As the disease positivity of RUT is more or less equal with PCR, patients can be treated based on RUT. Recommended for use in combination with either culture or histology, depending on local facilities. Figure 13

Figure 13: Depicts distribution of disease positivity :



Test	RUT	OGD	PCR	CAG	VAC
Positive(No s)	68	101	59	37	53
% of Positivity (POS/147) * 100	46	69	40	25	36

DISCUSSION

Helicobacter pylori is a Gram-negative organism which is microaerophilic, spiral shaped, slow-growing with processing flagella. Once infection is acquired in human it persists throughout the life, till completion of antimicrobial therapy. *H. pylori* colonization results mostly in chronic gastritis, followed by peptic ulcers and gastric adenocarcinomas. Investigation of *H. pylori* by Upper GI endoscope reveals the mucosal morphology of the gastric corpus as 4 types of patterns, duodenal ulcer and gastric ulcer. The invasive diagnostic methods such as Rapid urease test, histopathological examination and molecular biological methods, play a major role for detecting the species. *H. pylori* DNA have been detected in gastric biopsy specimens by PCR assays. Genes are classified as Cytotoxin associated gene (Cag A), Vacuolating cytotoxin associated gene (vac A), epithelial gene (ice A), blood group antigen binding adhesion gene (Bab A), and duodenal ulcer-promoting gene A (dupA). Cag A plays a role in duodenal ulcer, gastric cancer and gastro mucosal atrophy and Vac A in peptic ulceration.

The present study identified the mucosal patterns of *Helicobacter pylori* associated gastritis in the gastric corpus using video upper G.I endoscopy and compared with PCR which is confirmatory test. In addition we assessed the frequency of *H. pylori* virulence factors and their correlation with the clinical presentation and also we evaluated the association of virulence

genes of *H. pylori* to that of the mucosal changes on endoscopy and histopathology.

Alwahaibi et al. stated that among the 366 patients included in their study, 30.05 % patients were *H. pylori* positive based on histopathology⁽⁶⁹⁾. In another study, Hermann Brenner et al. reported a prevalence of 21 % (94/447) with ¹³C-urea breath test⁽³⁰⁾. Study by Leen-Jan Van Doorn et al. showed a positivity of 36.7% out of 493 cases based on PCR.⁽⁷⁰⁾ In this study of 147 patients, 59 patients (40%) were positive for *H. pylori* PCR.

Alwahaibi et al. also showed that *H. pylori* infection was more common in the younger age group (34.5%) followed by middle aged persons (30.9%). He further reports that female gender (36.9%) was more prone to develop *H. pylori* infection than the male gender (22.2%)⁽⁶⁹⁾. Kate et al also had similar kind of results being that of 63% men and 85% women positive for the infection⁽⁷¹⁾. This study also had a similar age distribution, the age group between 21 to 40 years contributed to the majority of the infected individuals in the study group (59%) followed by the middle age group those in-between 41 to 60 years (20%), these results are similar to studies by Alwahaibi and Kate but no gender differences were seen in this study group.

Leo et al. in a meta analysis states that epigastric pain had a positive correlation with *H. pylori*⁽⁷²⁾. In this study 44.4% with epigastric pain and 38.4%

with abdominal bloating showed positivity for *H. pylori*. Lin et al and Donohoe et al showed that clinical features had no correlation to *H. pylori* infection.

Hermann Brenner et al showed *H. pylori* had a positive correlation with coffee intake and smoking but had a negative correlation with alcohol consumption⁽³⁰⁾. In this study *H. pylori* was detected in 40% of coffee drinkers, 39% of smokers and 36% of alcohol abusers but none had a significant association with the non-substance abusers.

In this study, RUT sensitivity, specificity, PPV, NPV were 71.19%, 70.45%, 61.76% and 78.48% respectively which is lower when compared to the study by Lage et al who reported RUT sensitivity of 89.5% and specificity 97%.⁽⁷³⁾ Factors such as in house preparation of RUT medium could have resulted in batch variation.

We attempted to culture initial 40 biopsy samples but none of them grew *H. pylori*. Factors such as delay in transportation of samples to lab, in house media preparation, use of gas packs rather than CO₂ incubator could all have contributed to failure to isolate the organism from samples that were otherwise RUT and PCR positive. Further culturing of remaining samples were not undertaken.

Sheng-Lei Yan et al⁷ hypothesized that Type 1 and 2 mucosal patterns on endoscopy were good predictors of *H. pylori*-negative status while Type 3 and

type 4 mucosal patterns were good predictors of *H. pylori* positivity. This study is akin to the above study showing a high PCR positivity in type 3 & 4 gastritis in comparison to type 1 & 2 with a sensitivity of 84.38% and a specificity of 60% .

There is not much literature comparing *H. pylori* virulent genes to the mucosal patterns seen on endoscopy. The virulent Cag genes were positive in 4 patients of Type 1&2 ,17 patients of Type 3&4 and Vac genes were positive in 5 Type 1&2 ,24 patients of Type 3&4 . 5 patients of Cag genes and Vac genes were positive in duodenal ulcer patients . 39% of patients had PCR positivity in spite of a normal mucosa in conventional endoscopy , probably due to early stage of infection .

Kim et al found 91% showed histologic gastritis and 96% had *H. pylori* infection in his study population.⁽⁷⁴⁾ This study has demonstrated histologic gastritis in all the individuals which varied from non- specific gastritis to atrophic gastritis but *H. pylori* was found only in 3 patients. The possible reasons could be a sample not from the specified area, inadequate tissue size, defect in fixation, improper staining, thick microtome cutting of sections or excessive inflammatory cells & debris obscuring the organisms.

PCR positivity of glm gene of *H. pylori* was seen in 59(10.1%) patients of the study population. Meanwhile the incidence of the virulence genes by the way of only Cag positivity was seen in 6(10.3%) patients, only Vac positivity in 22(37.2%) patients and both virulence genes were seen in 31(52.5%) patients.

Among 37 Cag positive, 27 patients had gastritis and 10 patients had precancerous lesions. Cag only positive subgroup gastritis was seen in 4 of the 27 patients. Out of 37 Cag positive patients, 22 patients had both Cag and Vac gene positivity. 70% Cag positive patients were associated with gastritis.

Previous Vac genotype studies by Fukui et al. showed 81.25% of $s_{1c}m_{1b}$ where as Okinav et al. had predominant 70.4% $s_{1c}m_{1b}$. In this study, among 53 Vac positive patients, 20 (37.7%) patients had s_1m_1 , 27 (50.9%) patients had s_1m_2 and both positive was seen in 6 (11.4%) patients. Among patients with Vac positivity the subtype s_1m_2 constituted 50% while s_1m_1 was seen in 37.7% and both were seen in 11.3% of individuals.

In the VacA only positive sub group of the study, gastritis was seen in 17 patients out of the 38, and on subtyping, 6 had s_1m_1 , 9 had s_1m_2 and 2 persons had both s_1m_1 and s_1m_2 ;

In this study, 16 patients had intestinal metaplasia and 6 had atrophic gastritis. Out of 12/16 of intestinal metaplasia & 4/6 of atrophic gastritis patients were PCR positive, but in them s_1m_2 of Vac were predominantly associated with intestinal metaplasia and atrophic gastritis. This shows s_1m_2 of Vac is highly virulent and considered as precancerous. In contrast to Tomohisa Uchida et al.⁷⁵ which says s_1m_1 is more virulent and carcinogenic.

SUMMARY

In the study population of 147, 59 patients were positive for *H. pylori* diagnosed by the presence of genetic studies. Out of the 59 patients Type 1 and 2 gastritis were seen in 5 patients, while Type 3 and 4 gastritis were seen in 27 patients thus indicating a more severe gastritis seen in individuals infected with *H. pylori*.

Ulcers were seen in 9 patients out of which duodenal ulcer was seen in 7 patients while there were 2 patients with gastric ulcer. There were no mucosal abnormalities as observed on conventional endoscopy in 18 patients.

PCR positivity of *glm* gene of *H. pylori* was seen in 59(40%) patients of the study population, meanwhile the incidence of the virulence genes by the way of Cag positivity was seen in 6 patients, Vac positivity in 22 patients and both virulence genes were seen in 31. Among patients with Vac positivity the subtype s_1m_2 constituted 50% while s_1m_1 was seen in 37.7%, both were seen in 11.3% of individuals.

The predominant complaint in the study was abdominal bloating and epigastric pain, which had a 38.4% and 44.4% correlation with *H. pylori* PCR.

In the VacA only positive sub group of the study, gastritis was seen in 17 patients out of the 38, and on subtyping 6 patients had s_1m_1 , 9 patients had s_1m_2 and 2 persons had both s_1m_1 and s_1m_2 ; while in the Cag only positive subgroup gastritis was seen in 4 of the 27 patients.

In the VacA positive group precancerous lesions i.e., atrophic gastritis and intestinal metaplasia were seen in 7 patients on subtyping 6 patients in s₁m₂ and only one had both s₁m₁ and s₁m₂. In the Cag subgroup only one person had a precancerous lesion. In the subgroup who had both Cag and VacA genes, 22 had gastritis and 9 patients had precancerous lesion. There was significant correlation s₁/m₂ virulent gene of *H. pylori* to that of intestinal metaplasia and atrophic gastritis.

In this study there was an insignificant difference in between PCR and RUT, thus confirming that RUT even though a cheap test is valuable in establishing the diagnosis of *H. pylori* in an office setting.

CONCLUSION

- Our study identified predominant type 3 and 4 mucosal pattern followed by type 1 and type 2. Also PCR correlates well with type 3 and type 4 pattern.
- Among the prevalence of virulent genes, Vac gene is most common than Cag, with the predominant subtype being s₁m₂.
- There was significant correlation of *H. pylori* virulent genes s₁m₂ to that of intestinal metaplasia and atrophic gastritis
- In this study disease positivity of RUT is more or less equal with PCR , confirming that RUT is valuable in establishing the diagnosis of *H. pylori* .

LIMITATIONS :

- Conventionalendoscopy was used rather than amagnification endoscopy which would have been ideal in observing the mucosal pattern.
- Genomic extraction was done only for two genes Cag A and vac A.Other genes like ice A, Bab A anddupA has not been evaluated .
- Lack of workup for other causes of gastritis.

BIBLIOGRAPHY

BIBLIOGRAPHY

1. Blaser, M. J.. Ecology of *Helicobacter pylori* in the human stomach. *J Clin Invest* 1997;100, 759-762.
2. Parsonnet, J. *Helicobacter pylori* and gastric cancer. *Gastroenterol. Clin. North Am* 1993; 22:89–104.
3. Datta S, Chattopadhyay S, Patra R, De R, Ramamurthy T, Hembram J, et al. Most *Helicobacter pylori* strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. *Aliment Pharmacol Ther.* 2005 Jul 1;22(1):51-7.
4. Mukhopadhyay, A.K., Kersulyte, D., Jeong, J.Y., Datta, S., Ito, Y., Chowdhury, A., et al.. Distinctiveness of genotypes of *Helicobacter pylori* in Calcutta, India. *J. Bacteriol* 2000; 182(11): 3219– 3227.
5. Mishra, K.K., Srivastava, S., Dwivedi, P.P., Prasad, K.N., and Ayyagari, A. Genotypes of *Helicobacter pylori* isolated from various acid peptic diseases in and around Lucknow. *CurrSci* 2002; 83: 749–755.
6. Udhayakumar G, Senthilkumar C, Jayanthi V, Devaraj N, Devaraj |H. *Helicobacter pylori* detection and genotyping in gastric biopsy specimens from Chennai patients (India). *Can. J. Microbiol* 2009; 55: 126–132.
7. Sheng-Lei Yan, Shwu-Tzy Wu, Chien-Hua Chen, Yeh-Huang Hung, Tsung-Hsun Yang, Vun-Siew Pang, and Yung-Hsiang Yeh. Mucosal

patterns of *Helicobacter pylori*-related gastritis without atrophy in the gastric corpus using standard endoscopy *World J Gastroenterol*. 2010 January 28; 16(4): 496–500

8. Public Health England. Investigation of Gastric Biopsies for *Helicobacter pylori*. UK Standards for Microbiology Investigations. B 55 (2013).
9. Lu JJ, Perng CL, Shyu RY, Chen CH, Lou Q, Chong SK, Lee CH. Comparison of five PCR methods for detection of *Helicobacter pylori* DNA in gastric tissues. *J Clin Microbiol*. 1999 Mar;37(3):772-4.
10. Kumar S, Kumar A, Dixit VK. Genetic diversity in strains of *Helicobacter pylori* from India and their relatedness to strains from other parts of the world. *Infect Genet Evol*. 2011 Jan;11(1):242-7.
11. Thyagarajan SP, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S, et al. Geographical difference in antimicrobial resistance pattern of *Helicobacter pylori* clinical isolates from Indian patients: Multicentric study. *J Gastroenterol Hepatol*. 2003 Dec;18(12):1373-8.
12. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach patients with gastritis and peptic ulceration. *Lancet* 1984;1(8390): 1311-1315.
13. Graham DY, Lu H, Yamaoka Y. African, Asian or Indian enigma, the East Asian *Helicobacter pylori*: facts or medical myths. *J Dig Dis* 2009; 10 : 77-84.

14. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. *J Gastroenterol* 2010; 45 : 1-8.
15. Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. *Gastroenterology* 1997; 113 : 1983-91
16. Dikshit RP, Mathur G, Mhatre S, Yeole BB. Epidemiological review of gastric cancer in India. *Indian J Med PaediatrOncol* 2011; 32 : 3-11
17. SelviThirumurthi et al. Helicobacter pylori infection in India from a western perspective. *Indian J Med Res.* Oct 2012; 136(4): 549–562.
18. Mitchell HM: Epidemiology of infection. In *Helicobacter Pylori: Physiology and Genetics*. Edited by Mobley HLT, Mendz GL, Hazell SL. Washington, D.C.: ASM Press; 2001
19. Song Q, Lange T, Spahr A, Adler G, Bode G: Characteristic distribution pattern of Helicobacter pylori in dental plaque and saliva detected with nested PCR. *J Med Microbiol* 2000, 49:349-353.
20. Lin SK, Lambert JR, Schembri MA, Nicholson L, Korman MG: Helicobacter pylori prevalence in endoscopy and medical staff. *J GastroenterolHepatol* 1994, 9:319-324.
21. el-Zaatari FA, Nguyen AM, Genta RM, Klein PD, Graham DY: Determination of Helicobacter pylori status by reverse transcription-polymerase chain reaction. Comparison with urea breath test. *Dig Dis Sci* 1995, 40:109-113.

22. Perry S, de la Luz Sanchez M, Yang S, Haggerty TD, Hurst P, Perez-Perez G, Parsonnet J: Gastroenteritis and transmission of *Helicobacter pylori* infection in households. *Emerg Infect Dis* 2006, 12:1701-1708.
23. Leung WK, Sung JJ, Ling TK, Siu KL, Cheng AF: Use of chopsticks for eating and *Helicobacter pylori* infection. *Dig Dis Sci* 1999, 44:1173-1176.
24. Parsonnet J, Shmueli H, Haggerty T: Fecal and oral shedding of *Helicobacter pylori* from healthy infected adults. *JAMA* 1999, 282:2240-2245
25. Luzzza F, Mancuso M, Imeneo M, Contaldo A, Giancotti L, Pensabene L, Doldo P, Liberto MC, Strisciuglio P, Foca A, et al.: Evidence favouring the gastro-oral route in the transmission of *Helicobacter pylori* infection in children. *Eur J GastroenterolHepatol* 2000, 12:623-627
26. Bardhan PK: Epidemiological features of *Helicobacter pylori* infection in developing countries. *Clin Infect Dis* 1997, 25:973-978
27. Malaty HM, Engstrand L, Pedersen NL, Graham DY: *Helicobacter pylori* infection: genetic and environmental influences. A study of twins. *Ann Intern Med* 1994, 120:982-986.
28. de Martel C, Parsonnet J: *Helicobacter pylori* infection and gender: a meta-analysis of population-based prevalence surveys. *Dig Dis Sci* 2006, 51:2292-2301.

29. Rothenbacher D, Bode G, Berg G, Knayer U, Gonser T, Adler G, Brenner H: *Helicobacter pylori* among preschool children and their parents: evidence of parent-child transmission. *J Infect Dis* 1999, 179:398-402
30. Brenner H, Rothenbacher D, Bode G, Dieudonne P, Adler G: Active infection with *Helicobacter pylori* in healthy couples. *Epidemiol Infect* 1999, 122:91-95.
31. McCallion WA, Murray LJ, Bailie AG, Dalzell AM, O'Reilly DP, Bamford KB: *Helicobacter pylori* infection in children: relation with current household living conditions. *Gut* 1996, 39:18-21
32. Leunk RD, Johnson PT, David BC, et al. Cytotoxic activity in broth-culture filtrates of *Campylobacter pylori*. *J Med Microbiol* 1988;26:93-9.
33. Atherton JC, Cao P, Peek RM, et al. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. *J Biol Chem* 1995;270:17771-7.
34. Atherton JC, Peek RM, Tham KT, et al. Clinical and pathological importance of heterogeneity in *vacA*, the vacuolating cytotoxin gene of *Helicobacter pylori*. *Gastroenterology* 1997;112:92-9.
35. Covacci A, Censini S, Bugnoli M, et al. Molecular characterisation at the 128-kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer. *Proc Natl Acad Sci USA* 1993;90:5791-5.
36. Sharma SA, Tummuru MKR, Miller GG, et al. Interleukin-8 response of gastric epithelial cell lines to *Helicobacter pylori* stimulation in vitro. *Infect Immun* 1995;63:1681-7.

37. Censini S, Lange C, Xiang Z, et al. *cag*, a pathogenesis island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors. *Proc Natl Acad Sci* 1996;93:14648–53.
38. Aspinall GO, Monteiro MO, Pang H, et al. Lipopolysaccharide of the *Helicobacter pylori* type strain NCTC 11637 (ATCC 43504): structure of the O chain and core oligosaccharide regions. *Biochemistry* 1996;35:2489–97.
39. Wirth HP, Yang M, Karita M, et al. Expression of the human surface glycoconjugates Lewis X and Y by *Helicobacter pylori* isolates is related to *cagA* status. *Infect Immun* 1996;64:4598–605.
40. Crabtree JE. Gastric mucosal inflammatory responses to *Helicobacter pylori*. *Aliment Pharmacol Ther* 1996;10(suppl1):29–37.
41. Sobala G. M., Schorah C. J., Shires S., Lynch D. A. F., Gallacher B., Dixon M. F., Axon A. T. R. Effect of eradication of *Helicobacter pylori* on gastric juice ascorbic acid concentrations. *Gut*. 1993;34:1038–1041
42. Clyne M., Labigne A., Drumm B. *Helicobacter pylori* requires an acidic environment to survive in the presence of urea. *Infect. Immun.* 1995;63:1669–1673.
43. Mukawa K., Nakamura T., Nakano G., Nagamachi Y. Histopathogenesis of intestinal metaplasia: minute lesions of intestinal metaplasia in ulcerated stomachs. *J. Clin. Pathol.* 1987;40:13–18.

- 44.Eidt S., Oberhuber G., Schneider A., Stolte M. The histopathological spectrum of type A gastritis. *Path. Res. Pract.* 1996;192:101–106
- 45.Scott D. R., Marcus E. A., Weeks D. L., Lee A., Melchers K., Sachs G. Expression of the *Helicobacter pylori* urel gene is required for acidic pH activation of cytoplasmic urease. *Infect. Immun.* 2000;68:470–477
- 46.Walker M. M., Dixon M. F. Gastric metaplasia: its role in duodenal ulceration. *Aliment. Pharmacol. Ther.* 1996;10(Suppl. 1):119–128.
- 47.Wyatt J. I., Rathbone B. J., Dixon M. F., Heatley R. V. *Campylobacter pyloridis* and acid-induced gastric metaplasia in the pathogenesis of duodenitis. *J. Clin. Pathol.* 1987;40:841–848
- 48.Lanza F. L., Evans D. G., Graham D. Y. Effect of *Helicobacter pylori* infection on the severity of gastroduodenal mucosa injury after the acute administration of naproxen or aspirin to normal volunteers. *Am. J. Gastroenterol.* 1991;86:735–737.
- 49.Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? *Lancet* 1997;350:430–6.
- 50.Gasbarrini A, De Luca A, Fiore G, et al. Beneficial effects of *Helicobacter pylori* eradication on migraine. *Hepatogastroenterology* 1998;21:765–70.
- 51.Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of *Helicobacter pylori*. *Lancet* 1998;352:878.

52. Alkan S, Karcher DS, Newman MA, et al. Regression of salivary MALT lymphoma after treatment for *Helicobacter pylori*. *Lancet* 1996;348:268–9.
53. Tebbe B, Geilen CC, Schulzke JD, et al. *Helicobacter pylori* infection and chronic urticaria. *J Am Acad Dermatol* 1996; 34:685–6.
54. Mindel JS, Rosemberg EW. Is *Helicobacter pylori* of interest to ophthalmologists? *Ophthalmology* 1997;104:1729–30.
55. Farinati F, De Bona M, Floreani A, et al. *Helicobacter pylori* and the liver: any relationship? *Ital J Gastroenterol Hepatol* 1998;30:124–8.
56. Figura N, Cetta F, Angelico M, et al. Most *Helicobacter pylori*-infected patients have specific antibodies, and some also have *H. pylori* antigens and genomic material in bile. Is it a risk factor for gallstone formation? *Dig Dis Sci* 1998;43: 854–62.
57. Franceschi F, Gasbarrini A, Ricerca BM, et al. High prevalence of *H. pylori* infection in patients affected by idiopathic sideropenic anemia [abstract]. *Gut* 1998; (suppl 2):A106
58. Perri F, Pastore M, Leandro G, et al. *Helicobacter pylori* infection and growth delay in older children. *Arch Dis Child* 1997;77:46–9.
59. Megraud F, Lehours P. *Helicobacter pylori* detection and antimicrobial susceptibility testing. *Clin Microbiol Rev* 2007;20:280–322
60. Sheng-Lei Yan, Shwu-Tzy Wu, Chien-Hua Chen, Yeh-Huang Hung, Tsung-Hsun Yang, Vun-Siew Pang, and Yung-Hsiang Yeh. Mucosal patterns of *Helicobacter pylori*-related gastritis without atrophy in the

gastric corpus using standard endoscopy World J Gastroenterol. 2010

January 28; 16(4): 496–500

61. Tompkins D. Microbiological tests. In: Northfield TC, Mendall M, Goggin PM, editors. *Helicobacter pylori* infection. Dordrecht: Kluwer Academic Publishers; 1993. p. 116-26.
62. Thillainayagam AV, Arvind AS, Cook RS, Harrison IG, Tabaqchali S, Farthing MJ. Diagnostic efficiency of an ultrarapid endoscopy room test for *Helicobacter pylori*. GUT 1991;32:467-9.
63. McNulty CA, Wise R. Rapid diagnosis of *Campylobacter*-associated gastritis. Lancet 1985;1:1443-4
64. Vaira D, Vakil N. Blood, urine, stool, breath, money, and *Helicobacter pylori*. GUT 2001;48:287-9
65. Logan RP. Urea breath tests in the management of *Helicobacter pylori* infection. GUT 1998;43 Suppl 1:S47-S50
66. Ishihara S, Kaji T, Kawamura A, Rumi MA, Sato H, Okuyama T, et al. Diagnostic accuracy of a new non-invasive enzyme immunoassay for detecting *Helicobacter pylori* in stools after eradication therapy. Aliment Pharmacol Ther 2000;14:611-4
67. Hunt R, Thompson A, Consensus Conference participants. Canadian *Helicobacter pylori* Consensus Conference. Can J Gastroenterol 1998;12(1):31-41.

68. Katelaris PH, Forbes GM, Talley NJ, et al. A randomized comparison of quadruple and triple therapies for *Helicobacter pylori* eradication: The QUADRATE study. *Gastroenterology* 2002;123:1763–9
69. Nasar Y Alwahaibi, et al. The Prevalence of *Helicobacter Pylori* and Gastritis in Oman. *Journal of Digestive Endoscopy* 2013;4(2):29-32.
70. LEEN-JAN VAN DOORN et al. The Efficacy of Laboratory Diagnosis of *Helicobacter pylori* Infections in Gastric Biopsy Specimens Is Related to Bacterial Density and *vacA*, *cagA*, and *iceA* Genotypes. *JOURNAL OF CLINICAL MICROBIOLOGY*, 0095-1137/00/\$04.00 10 Jan. 2000, p. 13–17
71. V. Kate et al. anti *H. pylori* IgG seroprevalence in asymptomatic children and adults from south India *Indian journal of microbiology* 2001 19 (2).
72. Leo A. A Association Between *Helicobacter pylori* and Gastrointestinal Symptoms in Children *Pediatrics* 2010;125:e651
73. ANDREY P. LAGE et al. Diagnosis of *Helicobacter pylori* Infection by PCR: Comparison with Other Invasive Techniques and Detection of *cagA* Gene in Gastric Biopsy Specimens *JOURNAL OF CLINICAL MICROBIOLOGY* :Oct. 1995; p. 2752–2756.
74. Kim S, Ito M, Haruma K, Egi Y, Ueda H, Tanaka S, Chayama K. Surface structure of antral gastric mucosa represents the status of histologic gastritis. Fundamental evidence for the evaluation of antral gastritis by magnifying endoscopy. *J Gastroenterol Hepatol* 2006;21:837–841

75. Tomohisa Uchida et al, Analysis of virulence factors of *Helicobacter pylori* isolated from a Vietnamese population. *BMC Microbiology* 2009; **9**:175

MASTER CHART

MASTER CHART

	DDHD NO	age	SEX	C / F	PAST	person al	RUT	HPE	OGD	PCR	cag	vac
S. No	DDHD NO:	<20yrs-1 21-39-2 40-59-3 >60yrs-4	M=1 F=2	PPF-1;BL-2 ES-3;EB-4 AN-5;HB-6 NV-7;CP-8	DM-1 HT-2 DG-3 NIL-4	AL-1 SM-2 CO-3 SK-4 NO-5	1 = +ve / 2 = -ve	1 = CNG 2 = EG 3 = NG 4 = IM 5 = AG 6 = HP	1 = TYPE -1 / 2 = TYPE-2 3 = TYPE-3 4 = TYPE-4 5 = DU / 6 = GU / 7 = N	1=+ve 2 = ve	1=+v E 2= - VE	1= M1 + _{VE} 2=M2+ _{VE} 3=M1+M2+ _{VE} 4=-ve
1.	1494/13	3	2	1	1	5	1	1	7	2	2	4
2.	115/13	4	1	2	3	2	2	1	5	1	1	1
3.	186/13	2	1	4	4	3	1	1	7	1	2	2
4.	1857/13	3	1	5	2	5	2	1	7	2	2	4
5.	1709/13	1	1	2	4	1	2	6	7	2	2	4
6.	546/10	3	2	3	2	3	1	1	7	2	2	4
7.	1152/10	2	2	1	3	5	1	1	7	1	1	1
8.	606/13	2	1	2	4	2	1	1	2	2	2	4
9.	5725/6	2	1	5	3	2	1	1	2	2	2	4
10.	1804/11	2	2	6	4	3	1	2	7	2	2	4
11.	521/11	4	1	4	1	1	1	1	7	2	2	4
12.	1986/13	3	1	2	1	2	1	1	1	2	2	4
13.	317/12	2	1	2	4	3	1	1	3	2	2	4
14.	3524/13	1	2	4	4	5	1	1	1	2	2	4
15.	3519/13	2	1	4	2	1	1	1	7	2	2	4
16.	3526/13	3	1	8	4	1	1	1	3	2	2	4
17.	3528/13	2	1	6	4	5	2	1	3	2	2	4
18.	3688/13	2	1	4	4	1	1	6	7	1	1	3
19.	3806/13	1	2	8	4	5	2	3	7	2	2	4
20.	3804/13	2	1	2	4	3	1	3	3	1	1	2
21.	2021/13	3	1	7	3	2	1	2	3	1	1	2
22.	3869/13	2	1	6	4	5	2	2	1	2	2	4
23.	4011/13	2	2	3	1	3	1	1	2	2	2	4
24.	3895/13	2	1	1	4	1	1	1	7	2	2	4
25.	6295/10	2	2	4	1	5	1	2	3	2	2	4
26.	4256/13	2	1	4	4	2	1	1	7	2	2	4
27.	4266/13	3	2	2	2	5	1	3	7	1	1	1
28.	4472/12	2	1	3	4	1	2	5	3	1	1	2
29.	4470/13	3	2	2	2	3	2	2	3	2	2	4
30.	4791/13	1	1	2	4	2	1	1	3	1	1	4
31.	4422/13	2	1	1	4	1	1	1	7	1	1	4
32.	4378/13	2	1	4	4	3	1	1	5	2	2	4
33.	5104/13	3	2	5	3	4	2	2	1	1	2	2
34.	5270/13	2	1	6	1	4	1	2	3	1	2	1
35.	252/07	2	1	5	1	4	1	2	3	1	1	1
36.	230/05	3	2	3	1	5	2	2	2	1	1	2
37.	5400/13	2	2	2	2	3	1	1	7	1	1	2
38.	5405/12	3	1	1	3	5	2	1	1	2	2	4
39.	6894/11	2	1	4	4	1	2	1	7	2	2	4
40.	3148/09	2	1	5	1	3	1	3	5	1	2	2
41.	5506/13	3	1	2	3	3	1	1	7	2	2	4
42.	5001/13	2	1	8	4	2	1	1	3	2	2	4
43.	5440/13	2	1	1	1	5	2	1	7	1	2	3
44.	2894/13	2	1	2	1	1	2	4	5	2	2	4
45.	5524/13	2	2	5	4	5	1	1	3	1	2	2
46.	5527/13	2	2	2	4	5	1	2	7	1	2	2
47.	5549/13	3	2	5	2	3	2	3	7	2	2	4
48.	5517/13	3	1	4	1	5	1	2	3	1	2	2
49.	5578/13	2	1	3	3	2	1	1	2	1	1	2
50.	5939/13	3	1	4	2	2	1	1	7	1	1	1

51.	4388/13	2	1	5	1	3	2	1	7	2	2	4
52.	4169/13	3	1	2	2	1	2	2	6	2	2	4
53.	780/00	4	1	6	4	1	1	1	5	1	2	3
54.	5778/13	4	2	4	1	5	1	4	5	1	1	2
55.	5380/12	1	2	3	4	3	1	4	7	1	2	2
56.	5410/13	2	1	2	2	5	1	4	7	1	1	2
57.	5365/13	2	1	5	2	2	1	6	4	1	2	2
58.	5959/13	2	1	1	4	1	2	5	7	1	2	2
59.	6039/13	2	1	4	3	5	2	1	7	1	1	1
60.	5909/13	2	1	8	4	1	1	2	2	1	1	1
61.	6094/13	3	1	1	4	2	1	1	3	1	1	2
62.	6091/13	4	2	2	1	5	1	4	6	1	2	2
63.	6187/13	2	1	5	4	2	2	1	7	2	2	4
64.	6194/13	1	1	4	4	1	2	1	7	2	2	4
65.	6223/13	2	2	6	1	3	2	1	1	2	2	4
66.	6293/13	2	1	2	4	1	2	4	5	1	1	4
67.	6311/13	2	1	2	4	1	1	4	5	1	1	1
68.	625/11	2	1	4	1	5	2	4	3	1	1	1
69.	611/13	3	2	6	1	5	2	2	1	2	2	4
70.	6325/13	4	2	5	4	5	2	4	2	2	2	4
71.	6335/13	3	2	4	3	5	1	1	3	1	1	2
72.	6219/13	3	1	2	4	2	2	4	2	2	2	4
73.	2755/00	3	2	6	2	3	2	1	2	2	2	4
74.	4833/13	3	1	1	1	2	2	1	1	2	2	4
75.	7343/13	3	1	8	4	5	2	2	1	2	2	4
76.	5845/13	3	1	4	2	2	2	1	7	2	2	4
77.	5474/13	1	2	5	4	5	2	3	2	2	2	4
78.	6509/13	2	1	1	2	1	2	1	1	2	2	4
79.	208/11	3	1	2	1	1	2	3	7	2	2	4
80.	6550/13	2	1	6	4	2	1	5	7	1	1	1
81.	6500/13	4	2	1	3	5	2	2	2	2	2	4
82.	6499/13	2	1	2	2	2	1	4	3	1	1	2
83.	6331/13	2	1	4	1	3	2	1	6	1	2	4
84.	6656/13	4	1	5	3	1	1	2	3	1	1	4
85.	6648/13	4	1	3	1	1	1	3	3	1	1	4
86.	4487/13	3	1	2	1	1	1	1	3	2	2	4
87.	6276/13	2	2	4	4	2	1	1	7	2	2	4
88.	6659/13	4	1	1	1	2	1	1	2	1	1	3
89.	829/13	2	1	6	4	1	2	2	5	2	2	4
90.	6294/13	3	2	2	2	2	1	1	3	2	2	4
91.	6509/13	4	1	4	4	2	2	1	6	2	2	4
92.	6672/13	2	1	4	4	4	2	3	7	2	2	4
93.	6806/13	2	2	6	1	3	1	1	7	2	2	4
94.	6706/13	4	2	2	3	1	2	1	7	2	2	4
95.	3220/13	2	1	4	1	5	1	1	5	2	2	4
96.	8871/13	4	1	5	1	3	2	1	2	2	2	4
97.	6861/13	2	1	2	4	2	2	1	6	2	2	4
98.	6589/13	4	1	5	2	2	2	5	5	2	2	4
99.	6986/13	2	1	4	4	1	2	4	3	1	2	3
100.	6952/13	3	1	5	1	5	2	1	1	2	2	4
101.	6994/13	2	2	1	4	2	2	3	7	2	2	4
102.	5396/13	2	1	4	4	1	2	2	6	2	2	4
103.	6948/13	2	2	4	1	2	1	1	3	1	1	1
104.	7124/13	3	1	2	2	3	2	4	5	2	2	4
105.	7258/13	4	1	5	1	4	2	5	5	2	2	4
106.	7312/13	3	1	2	4	1	2	4	3	2	2	4
107.	7319/13	2	1	1	4	5	2	2	2	2	2	4
108.	7346/13	2	2	1	1	5	1	1	5	1	1	4
109.	7340/13	4	1	2	3	1	2	1	2	2	2	4
110.	7354/13	4	1	4	2	5	2	1	3	2	2	4
111.	7394/13	2	1	2	4	5	2	1	3	2	2	4
112.	3129/10	3	1	4	1	2	1	1	7	1	2	1
113.	7513/13	2	1	5	1	1	2	1	4	1	2	1
114.	7591/13	2	1	2	2	1	1	1	7	1	1	1

115.	1542/13	2	1	1	3	2	2	1	1	2	2	4
116.	7498/13	2	1	4	3	1	2	1	3	2	2	4
117.	7611/13	2	1	1	1	3	2	3	3	1	2	1
118.	6997/12	1	1	4	4	4	2	1	3	2	2	4
119.	7450/13	2	2	2	1	3	2	1	2	2	2	4
120.	7589/13	2	1	1	4	5	2	1	3	1	2	2
121.	7491/13	4	1	6	3	1	1	3	3	1	1	1
122.	8077/11	2	1	7	4	5	2	1	6	2	2	4
123.	7568/13	3	1	2	2	1	2	1	2	2	2	4
124.	7539/13	3	2	3	1	2	2	1	1	2	2	4
125.	45/14	2	1	2	4	5	2	1	5	2	2	4
126.	96/14	3	1	2	1	2	2	1	7	2	2	4
127.	58/14	3	1	4	4	1	2	3	7	2	2	4
128.	104/14	4	1	5	3	1	1	1	2	2	2	4
129.	128/14	2	2	4	2	5	2	1	7	1	1	1
130.	7244/13	3	1	1	2	5	2	2	3	2	2	4
131.	154/14	2	1	2	4	4	2	3	3	2	2	4
132.	197/14	3	2	6	1	5	2	2	3	2	2	4
133.	6996/09	3	1	5	3	1	2	1	7	2	2	4
134.	194/14	2	1	8	4	5	2	1	3	2	2	4
135.	3446/10	2	1	2	4	5	1	4	7	1	2	2
136.	269/14	2	1	4	1	4	1	1	3	1	1	3
137.	302/14	3	2	5	3	1	2	1	2	2	2	4
138.	225/14	4	2	1	3	3	1	2	3	1	2	1
139.	7967/11	2	1	4	4	2	2	1	7	2	2	4
140.	386/14	4	1	2	2	5	1	1	3	1	2	2
141.	361/14	2	2	6	4	5	2	1	5	2	2	4
142.	517/14	3	2	2	1	3	2	2	7	1	2	1
143.	497/11	1	1	4	4	5	2	1	5	2	2	4
144.	3226/03	2	1	4	4	1	1	4	3	1	1	2
145.	7317/13	3	1	2	2	2	1	1	3	1	1	2
146.	7513/13	3	2	5	1	3	2	4	4	1	2	4
147.	7542/13	4	1	4	3	2	1	5	3	1	2	2

Age

clinical features

past history

personal history

<20 years-1 PPF-post prandial fullness-1 DM- diabetes-1 AL-alcohol intake-1
 21-39 years -2 BL- abdominal bloating-2 HT- hypertension-2 SM-smoking-2
 40-59 years -3 ES -early satiety -3DG- drug intake-3 CO-coffee-3
 >60 years -4 EB-epigastric burning-4 NIL-no past history -4 SK-skip meals-4
 AN-relived by antacids -5;
 HB-heart burn -6
 NV- nausea &vomiting -7;
 CP-atypical chest pain-8

RUT- rapid urease test

HPE- histopathological

OGD findings

Positive- 1
Negative- 2

1 = CNG-chronic non -specific gastritis
 2 = EG- erosive gastritis
 3 = NG- nodular gastritis
 4 = IM- intestinal metaplasia
 5 = AG-atrophic gastritis
 6 = HP- h. pylori

1 = TYPE -1
 2 = TYPE-2
 3 = TYPE-3
 4 = TYPE-4
 5 = DU- duodenal ulcer
 6 = GU – gastric ulcer
 7 = N- normal muocosa

PROFORMA

PROFORMA

NAME :

AGE/SEX :

DDHD no:

HISTORY:

POSTPRANDIAL FULLNESS:

UPPER ABDOMINAL BLOATING:

EARLY SATIETY:

EPIGASTRIC BURNING :

RELIEVED BY

ANTACIDSBELCHING:

WATER BRASH:

ODYNOPHAGIA

:

NAUSEA:

VOMITING:

HEARTBURN:Chest Pain:

PURPURA:

EASY

FATIGUBILITY:

PAST HISTORY

DM:

SHT:

TB:

IHD :

DRUG/ NSAID / ASA INTAKE:

PERSONAL HISTORY:

SMOKING:

ALCOHOL :

SKIPPING OFMEALS :

TOBACCO:

CAFFINE:

Emotional stress :

Sleep Pattern :

FAMILY HISTORY:

Similar illness :

GENERAL EXAMINATION:

CONSCIOUS/ORIENTED:

PALLOR:

ICTERUS:

CYANOSIS:

CLUBBING:

EDEMA:

LYMPHADENOPATHY:

PURPURA:

OTHER SIGNS:

VITALS:

HT:

WT:

BMI:

PULSE:

BP:

TEMP:

URINE OUTPUT:

SYSTEMIC EXAMINATION:

ORAL CAVITY:

P/A :

R.S :

CVS:

CNS:

INVESTIGATIONS:

Hb :

ESR:

TC :

DC:P

L

E

M

BT:

CT:

PI COUNT:

RBS:

UREA:

CREATININE:

ECG:

CHEST X RAY:

USG ABDOMEN:

Date -

OGD REPORT:

RUT:

HPE:**C/S:**

AMOX:

METRO:

CLARITHROMYCIN:

TETRACYCLINE:

LEVOFLOXACIN:

BISMUTH:

RIFABUTIN:

PCR:glmm:

cag PAI :

Vac A - S1M1 :

S1 M2:


INSTITUTIONAL ETHICAL COMMITTEE
GOVT.KILPAUK MEDICAL COLLEGE,
CHENNAI-10
Ref.No.10499/ME-1/Ethics/2012 Dt:06.12.2012.
CERTIFICATE OF APPROVAL

The Institutional Ethical Committee of Govt. Kilpauk Medical College, Chennai reviewed and discussed the application for approval "A Study on Occurrence of virulent strains of helicobacter pylori and its association with endoscopic findings in a tertiary centre teaching hospital in chennai" for dissertation purpose submitted by Dr.V.Anand, 2nd year DM.,Gastroenterology, PG Student, Kilpauk Medical College Chennai.

The Proposal is APPROVED.

The Institutional Ethical Committee expects to be informed about the progress of the study any Adverse Drug Reaction Occurring in the Course of the study any change in the protocol and patient information /informed consent and asks to be provided a copy of the final report.




CHAIRMAN, 11/3/14
Ethical Committee
Govt.Kilpauk Medical College,Chennai

